LLY vs ABT
By Alex · Tickerpine
Eli Lilly and Company vs Abbott Laboratories, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | ABT |
|---|---|---|
| Price | $1,183.46 | $101.29 |
| Market cap | $1.06T | $175.27B |
| P/E ratio | 39.7 | 32.8 |
| ROE | 102.29% | 10.58% |
| Profit margin | 33.53% | 11.65% |
| Revenue growth | 47.70% | 13.00% |
| Dividend yield | 0.58% | 2.49% |
| Beta | 0.50 | 0.59 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs ABT in plain English
- LLY is the bigger company — about 6.0× the market cap of ABT.
- ABT is cheaper on earnings (P/E 32.8 vs 39.7).
- LLY earns a higher return on equity (102% vs 11%).
- LLY is growing revenue faster (48% vs 13%).
- ABT has the higher dividend yield (2.49% vs 0.58%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
ABT return calculator
See what $1,000 in Abbott Laboratories would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.